title: Blinatumomab: first global approval.
abstract: Blinatumomab (BLINCYTO™) is a novel, bispecific T-cell engaging antibody that binds cluster of differentiation (CD) 19 antigens on blast cells while also binding and activating the CD3/T cell receptor complex, causing cell lysis. The antibody is being developed by Amgen as a treatment for haematological cancers that originate from B cell lines. Blinatumomab was approved by the US FDA in December 2014 for the treatment of adults with Philadelphia chromosome (Ph)-negative relapsed/refractory B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). It is awaiting approval for this indication in the EU and is in phase III development in various countries. This article summarizes the milestones in the development of blinatumomab leading to its first approval for the treatment of Ph-negative BCP-ALL.
authors: Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand, dru@adis.com.
authors: Mark
authors: M
authors: Sanford
mesh_terms: D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D005062:European Union; D006801:Humans; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D014481:United States
chemical_list: D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; C510808:blinatumomab
references: J Clin Oncol. 2014 Dec 20;32(36):4134-40
references: 25385737
references: J Clin Oncol. 2011 Jun 20;29(18):2493-8
references: 21576633
references: Blood Cancer J. 2014 Sep 05;4:244
references: 25192414
references: Drugs. 2011 Mar 5;71(4):415-42
references: 21395356
references: Leuk Res. 2009 Mar;33(3):465-73
references: 18835037
references: Haematologica. 2013 Dec;98(12):1930-8
references: 23812940
references: Clin Pharmacol. 2013 Apr 12;5(Suppl 1):5-11
references: 23671399
references: Blood. 2012 Jun 28;119(26):6226-33
references: 22592608
references: Haematologica. 2014 Jul;99(7):1212-9
references: 24727818
references: Blood. 2012 Dec 20;120(26):5185-7
references: 23024237